Background: Contrast-enhanced endoscopic ultrasound-guided fine needle aspiration (CE-EUS-FNA) could help clinicians to precisely locate and puncture lesions, but its effect on the diagnostic yield improvement is controversial. We designed this study to observe the additional benefit of using contrast in EUS-guided tissue sampling while performing fine needle biopsy (FNB) instead of FNA, as FNB results in a higher diagnostic accuracy. Method: Patients who underwent EUS-FNB performed by a single medical team from January 2019 to March 2021 were included in this study. We analyzed the cytopathological diagnostic accuracy rate and number of needle passes between groups who underwent FNB with and without contrast. Result: We divided 133 patients who were diagnosed with a malignancy into two groups according to whether they underwent CE-EUS-FNB (n = 48) or conventional EUS-FNB (n = 85). The CE-EUS-FNB group had an equal diagnostic accuracy rate with fewer needle passes compared with the conventional EUS-FNB group. There was no significant trend change in the success cytopathological diagnostic rate for experienced endoscopists for EUS-FNA. Conclusion: CE-EUS-FNB had fewer needle passes but no additional benefit for diagnostic yield improvement. There was no difficult threshold for CE-EUS-FNB for endoscopists who were well trained in conventional FNA.
Diagnosing pancreatic malignancy is challenging, especially in patients with chronic pancreatitis (CP). Endoscopic ultrasonography (EUS) is a promising diagnostic procedure for discriminating between malignancy and CP. We aimed to investigate the predictive factors and reliability of computed tomography (CT) and EUS for differentiating pancreatic mass lesions and the diagnostic accuracy of EUS-FNA or FNB in patients with CP. Forty patients with CP, receiving CT and EUS-FNA or FNB for pancreatic mass lesion evaluation, were enrolled in the study. Patients’ data, CT and EUS characteristics, image-based diagnosis, cytopathology, and final diagnosis were recorded. EUS was superior to CT in terms of diagnostic accuracy (92.5% vs. 82.5%, p = 0.02). Both CT and EUS showed significant predictive factors (all p < 0.05) with the tumor image hypoattenuation pattern or vessel invasion on CT and pancreatic duct dilatation, or distal pancreatic atrophy on EUS. EUS imaging is a reliable modality for evaluating pancreatic lesions, even with a CP background. The EUS image has a higher diagnostic accuracy than CT. Predicting factors, including hypoechoic pattern, pancreatic duct dilatation, and distal pancreas atrophy, may help to differentiate benign or malignant in patients with CP.
Endoscopic ultrasonography (EUS) is pivotal for diagnosing and sampling pancreatic tumor tissues. This study aimed to assess how the histological type and size of tumors influence the adequacy of macroscopic tissue cores acquired using EUS-guided fine needle biopsy (FNB). We conducted a retrospective study involving 180 patients with pathologically confirmed pancreatic malignancies at our hospital, a medical center, between July 2020 and June 2023. Personal and clinical data, EUS findings, and pathological results were extracted from the patient records. The macroscopic tissue core acquisition rate was 86.1%. Patients with tumors larger than 3 cm had a higher sufficiency rate (93.3%) compared to those with tumors 3 cm or smaller (78.9%, p = 0.005). It was more difficult to obtain sufficient tissue cores from neuroendocrine tumors than from adenocarcinomas (67.7% vs. 89.9%, p = 0.001). Interestingly, obtaining a sufficient tissue core only affected the diagnostic rate of adenocarcinoma (93.3% vs. 60%, p < 0.001) but did not significantly influence the diagnostic rate of neuroendocrine tumors. This study highlights that small tumors (< 3 cm) and neuroendocrine tumors pose a challenge in obtaining sufficient tissue cores. However, obtaining sufficient tissue cores significantly influences the pathological diagnosis of FNB in adenocarcinoma but not in neuroendocrine tumors.
Clinicians often use endoscopic ultrasonography to survey pancreatic tumors. When endoscopists conduct this examination and find the tumor to be unresectable, a fine-needle biopsy is subsequently performed for tissue confirmation. However, if the tumor is deemed resectable, the necessity of a pre-operative fine-needle biopsy remains debatable. Therefore, we performed a retrospective analysis of a single-center cohort of patients with pancreatic tumors who underwent an endoscopic ultrasound-guided fine-needle biopsy or aspiration (EUS-FNB or FNA) between 2020 and 2022. This study focused on patients diagnosed with resectable malignant pancreatic tumors. The exclusion criteria included individuals diagnosed with benign pancreatic lesions and those with unresectable tumors. A total of 68 patients were enrolled in this study. Histological examination revealed that pancreatic adenocarcinoma was the predominant type of tumor (n = 42, 61.8%), followed by neuroendocrine tumors (n = 22, 32.3%), and metastasis (n = 4, 5.9%). Notably, 17 patients had a history of other cancers, with 23.5% being diagnosed with a metastatic tumor rather than primary pancreatic cancer. Therefore, EUS-FNA/FNB is crucial in patients with a resectable pancreatic tumor and a history of cancer to differentiate between a primary and a metastatic tumor.
Endoscopic ultrasound (EUS) is a highly sensitive imaging modality for detecting pancreatic tumors, particularly small lesions. However, its ability to distinguish malignant from benign lesions remains a diagnostic challenge. This study aimed to evaluate the imaging characteristics observed via EUS in differentiating malignancy and to assess the influence of tumor size on diagnostic accuracy. This retrospective study included 315 patients who underwent EUS evaluation for pancreatic tumors between January 2019 and July 2024. The final diagnosis was established based on surgical pathology, EUS-FNB results, or clinical follow-up ≥ 6 months. Key imaging features assessed included echogenicity, lesion margins, pancreatic duct dilatation, and distal pancreatic atrophy. Tumors were categorized by size (< 2 cm or > 2 cm), and statistical analyses were conducted to identify predictive factors of malignancy. Of the 315 tumors, 205 (65.1%) were malignant. Five EUS imaging features-hypoechoic pattern, heterogeneous echotexture, irregular margins, pancreatic duct dilatation, and distal pancreatic atrophy-were identified as predictive of malignancy. The ROC-derived cutoff of 3.5 corresponds clinically to ≥ 4 features. AUC was 0.807 (95% CI: 0.759-0.849). Using a ≥ 4-feature threshold, sensitivity was 87.8%, specificity 54.5%, PPV 78.6%, and NPV 69.4%. Subgroup multivariable analysis revealed that heterogeneous echotexture and pancreatic duct dilatation were significant predictors of malignancy in tumors < 2 cm. However, in tumors > 2 cm, no individual feature significantly distinguished malignancy. Among pancreatic tumors, those exhibiting four or more of the five EUS features should be prioritized for malignancy evaluation. In small tumors, heterogeneous echotexture and pancreatic duct dilatation offer valuable diagnostic insight. Conversely, larger tumors present greater diagnostic challenges due to overlapping features on B-mode imaging alone.
16 October 2025 in World Journal of Gastrointestinal Endoscopy
Endoscopic ultrasonography (EUS) is a valuable and widely used tool for evaluating pancreatic tumors. Accurate decision-making during EUS procedures, particularly for differentiating between benign and malignant lesions based on imaging characteristics and assessing the need for tissue sampling, is crucial. This review provides a comprehensive overview of pancreatic tumor features observed during EUS and highlights the key criteria for distinguishing between malignant and benign conditions. Additionally, we discuss the indications for fine-needle aspiration or biopsy to obtain histopathological and genetic confirmation. Improving our understanding of these critical aspects can help improve diagnostic accuracy and guide clinicians in determining the most appropriate management strategies for patients with pancreatic tumors.